News & Resources

2023 Tips for Strengthening KOL Engagement

If you have ever worked for a pharmaceutical company, you’ve likely heard the ubiquitous term “KOL” several dozen times. But do you know what—or rather who—a KOL actually is?

Also known as a “key opinion leader,” a KOL is regarded as an important figure providing vital counsel to the healthcare industry. Specifically, a KOL is an independent scientific partner, expert, or advisor whose voice is highly respected within their specific therapeutic field.

Because of the swiftly changing nature of the healthcare landscape, approaches to pharmaceutical marketing must evolve with the product or service. Enter KOLs, whose role it is to offer opinions and expertise, with support from a broad professional network. KOLs function as crucial resources to the pharmaceutical industry, as they provide an understanding of the product’s life cycle as well as what is required to achieve market access.

What Do KOLs Provide?
The counsel provided by KOLs applies to a range of activities, from a product’s initial research and development phase to market access. KOLs understand not only the pharmaceutical processes of developing and marketing new treatments, but also how the treatments benefit patients. They may be engaged to help design outcome-based clinical trials, accelerating a new treatment to market. KOLs further help healthcare providers understand the treatment value and help determine how to get the treatment to the patients who need it most (the care pathway).

With more regulations surrounding the practice of healthcare, along with greater complexity of the science behind the products, KOL involvement is now required in more diverse activities. Today, KOL engagement guides companies in developing new products, conducting research and generating data, refining the commercialization strategy, and creating quality medical and promotional content.

What Drives a KOL Partnership?
While many companies use KOLs, they don’t always actively engage their KOL resources or necessarily work to form a true partnership. Deep and meaningful scientific dialogues afforded by key opinion leaders can lead to strong KOL partnerships, ultimately enhancing patient care. So what factors motivate KOLs to partner with a pharmaceutical company in the first place?

It’s important to remember that a partnership should be mutually beneficial. That said, factors that motivate KOLs to work with you include provisional education and training experiences. KOLs by definition are driven by growth: they want to achieve the highest level of education and have access to the most current information. Furthermore, KOLs look for opportunities to be involved in research or clinical trials. As specialists in their field, they have a genuine interest and desire to contribute to medical advances.

Sponsorships provide KOLs the unique opportunity to work in modern labs with access to cutting-edge equipment. Having a hand in the development of innovative new treatments is appealing for a KOL entering a partnership. Likewise, contributing to new clinical outcomes and analyzing unpublished data can help pave the way for KOLs to receive peer recognition, a big factor for KOLs considering a partnership with a pharmaceutical company.

How Do You Strengthen KOL Engagement?
A survey by the Medical Science Liaison (MSL) society shows that KOL management and education are top MSL activities. To help your company make the most of your KOL partnerships, here are a few tips for high-quality engagement of KOLs

  • Utilize an objective-driven approach to KOL engagement. Specific scientific and business goals should be clearly defined for all sides, and should be used to drive engagement activities. By employing a KOL-profiling procedure, you can more effectively engage these valuable individuals. The better you can recognize your KOLs’ distinctive interests, the better you can utilize them. Well-planned KOL engagement that supports your objectives throughout the product life cycle will ultimately provide your product a critical competitive edge
  • Develop a unique KOL engagement plan. As a company, it’s important to define a plan for how to engage and manage KOLs—this helps provide your employees a bigger picture of a KOL’s role. Your engagement plan should address the scientific and medical needs of your KOLs to support mutually beneficial relationships. Involving KOLs in the discussion is a terrific way to create a successful plan
  • Anticipate your KOLs’ needs. When you communicate regularly, and your KOLs begin to open up to you, you will be more aware of problems or expectations that could undermine the partnership. By understanding what your KOL needs, you can quickly offer solutions, winning their trust and gaining efficiency
  • Create opportunities to collaborate with your KOLs beyond the pharmaceutical industry. Cross-functional expert work groups or advisory boards meet to pursue common aspirations pertaining to medical science, and can appeal to KOLs. You may also facilitate international networking on behalf of your KOL or invite collaboration with colleagues in other therapeutic areas
  • Embrace KOL feedback. The best way to actively engage with your KOLs is to encourage and invite their opinions on how to improve your company’s products or services. Creating dialogue with your KOLs can help you improve not only your product (helping you modify the concept, service, or commercial message), but also your status as a partner

Summary
Meeting with KOLs in person is critical; face-to-face meetings can help solidify a KOL’s commitment to your company. In forming a respectful partnership, make sure to have the appropriate staff conduct interactions and lead scientifically focused discussions. Meetings should be well planned to maximize your KOLs’ time. Furthermore, acknowledging the KOLs’ opinions and feedback, as well as their time commitment, is extremely important. In recruiting KOLs, use peer-to-peer recommendations to help build a strong KOL network, as well as expand your access to valuable resources. For the most effective collaboration, consider the individual KOL’s interests, strengths, and alignment with the company’s goals for a particular product or service.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.